We are live on ! Find out more
AMRI

Albany Molecular Research Inc
AMRI

Delisted

AMRI was delisted on the 31st of August, 2017.

142 hedge funds and large institutions have $394M invested in Albany Molecular Research Inc in 2016 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 58 increasing their positions, 38 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

53% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 38

17% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 12

1% more funds holding

Funds holding: 141142 (+1)

17% less capital invested

Capital invested by funds: $472M → $394M (-$78.7M)

98% less call options, than puts

Call options by funds: $1.47M | Put options by funds: $65.1M

Holders
142
Holders Change
+1
Holders Change %
+0.71%
% of All Funds
3.79%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
14
Increased
58
Reduced
38
Closed
12
Calls
$1.47M
Puts
$65.1M
Net Calls
-$63.7M
Net Calls Change
+$8.61M
Name Holding Trade Value Shares
Change
Change in
Stake
EA
26
Emerald Acquisition
Washington
$3.19M +$3.46M +237,454 New
Fisher Asset Management
27
Fisher Asset Management
Washington
$2.93M
SAMC
28
Shinko Asset Management Company
Japan
$2.73M
Principal Financial Group
29
Principal Financial Group
Iowa
$2.57M +$89.8K +6,155 +3%
Geode Capital Management
30
Geode Capital Management
Massachusetts
$2.53M +$39.8K +2,726 +1%
PTC
31
Philadelphia Trust Company
Pennsylvania
$2.45M +$38.7K +2,650 +1%
Natixis Advisors
32
Natixis Advisors
Massachusetts
$2.3M +$85.1K +5,831 +4%
Deutsche Bank
33
Deutsche Bank
Germany
$2.23M -$798K -54,680 -25%
California Public Employees Retirement System
34
California Public Employees Retirement System
California
$1.95M -$19K -1,300 -0.9%
Ameriprise
35
Ameriprise
Minnesota
$1.76M +$65.6K +4,500 +4%
Invesco
36
Invesco
Georgia
$1.7M -$168K -11,540 -8%
MAP
37
Moody Aldrich Partners
Massachusetts
$1.68M +$1.15M +78,752 +169%
CSC
38
Cove Street Capital
California
$1.61M
BIM
39
BlackRock Investment Management
Delaware
$1.59M +$265K +18,190 +18%
Renaissance Technologies
40
Renaissance Technologies
New York
$1.58M -$2.99M -205,300 -64%
AA
41
Ancora Advisors
Ohio
$1.54M +$146K +10,000 +10%
JP Morgan Chase
42
JP Morgan Chase
New York
$1.37M +$202K +13,840 +16%
MOACM
43
Mutual of America Capital Management
New York
$1.35M +$39.3K +2,694 +3%
GC
44
Guggenheim Capital
Illinois
$1.32M -$121K -8,309 -8%
Bessemer Group
45
Bessemer Group
New Jersey
$1.23M
FSA
46
Franklin Street Advisors
North Carolina
$1.14M -$274K -18,775 -18%
TCIM
47
TIAA CREF Investment Management
New York
$1.11M +$19.7K +1,352 +2%
Goldman Sachs
48
Goldman Sachs
New York
$1.11M +$270K +18,525 +29%
Citadel Advisors
49
Citadel Advisors
Florida
$1.07M +$820K +56,182 +241%
RIM
50
Ranger Investment Management
Texas
$1.01M +$44.5K +3,050 +4%

AMRI Hedge Fund Activity: Q2 2016 in Review

142 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Albany Molecular Research Inc (AMRI) for Q2 2016, worth a combined $394M — down 17% from $472M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new AMRI positions and 12 closed out — a net gain of 2 holders — while 58 added to existing stakes and 38 trimmed.

The largest buyer was Permian Investment Partners, adding an estimated $22.5M. The largest seller was Visium Asset Management, exiting entirely with an estimated $30.7M sold.

  • 142 institutional investors held Albany Molecular Research Inc (AMRI) as of Q2 2016, up from 141 in Q1 2016.
  • Funds reported $394M of Albany Molecular Research Inc stock for Q2 2016, down 17% quarter-over-quarter.
  • 14 funds opened new Albany Molecular Research Inc positions in Q2 2016 and 12 closed out, a net change of +2 holders.
  • The largest Albany Molecular Research Inc buyer in Q2 2016 was Permian Investment Partners, an estimated $22.5M added.
  • The largest Albany Molecular Research Inc seller in Q2 2016 was Visium Asset Management, an estimated $30.7M sold.

Based on aggregated 13F filings for Q2 2016.